The global liraglutide and semaglutide market accounted for USD 15.87 billion in 2023 and is expected to reach USD 51.83 billion by 2034 with a CAGR of 11.36% during the forecast period 2024-2034. The market will grow due to factors such as the increasing prevalence of type 2 diabetes and obesity, patient preference for injectable therapies, emphasis on lifestyle modification and weight management, developments in drug delivery technologies, and comprehensive disease management plans.
Healthcare professionals are increasingly adding liraglutide and semaglutide to complete treatment programs as a result of a growing understanding of the significance of lifestyle adjustment in the management of type 2 diabetes and obesity. These drugs are useful components of multimodal therapy approaches because they boost weight loss efforts in addition to helping manage blood sugar levels. For instance, in March 2023, Eli Lilly and Company reported favorable findings from a Phase 3 clinical trial assessing the safety and effectiveness of its once-weekly GLP-1 receptor agonist under consideration for weight management.
By type, the liquid segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the ease of administration and patient preference for injectable formulations, driving increased adoption and sales of liraglutide and semaglutide solutions. For instance, Novo Nordisk revealed encouraging findings from the SUSTAIN 11 trial in October 2022, proving the safety and effectiveness of once-weekly semaglutide in lowering significant adverse cardiovascular events in individuals with type 2 diabetes. Additionally, the pills segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience and patient preference for oral administration, as well as advancements in pill formulations improving efficacy and tolerability.
By route of administration, the parenteral segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the direct delivery of the medication into the bloodstream, ensuring rapid onset of action and precise dosing control, which are particularly beneficial for managing conditions like diabetes and obesity. For instance, in September 2023, Eli Lilly announced the start of the SURPASS-CVOT study, which aims to assess the cardiovascular efficacy and safety of tirzepatide with semaglutide in people with existing cardiovascular disease and type 2 diabetes. Additionally, the oral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for convenient and non-invasive treatment options, driving innovation in oral formulations, and expanding patient access to liraglutide and semaglutide therapies.
By application, the type 2 diabetes mellitus segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the growing prevalence of type 2 diabetes mellitus worldwide, driving the demand for effective glucose-lowering therapies such as liraglutide and semaglutide. For instance, AstraZeneca reported encouraging findings from the SURPASS-2 trial in December 2023, showing that once-weekly semaglutide significantly reduced HbA1c and body weight in persons with type 2 diabetes when compared to dulaglutide. Additionally, the obesity segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of obesity as a significant health concern and the efficacy of liraglutide and semaglutide in weight loss, driving greater adoption for obesity management.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the preference for hospital-based administration of injectable medications like liraglutide and semaglutide, especially for acute management and closely monitored care of patients with diabetes and obesity-related complications. For instance, Sanofi announced in January 2024 the start of the AMPLITUDE-O study, which compares the safety and effectiveness of once-weekly semaglutide vs once-weekly efpeglenatide in individuals with type 2 diabetes. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of online platforms for medication purchases, the convenience of home delivery, and expanded access to liraglutide and semaglutide for patients in remote areas or with limited mobility.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes and obesity, robust healthcare infrastructure, and early adoption of advanced therapies like liraglutide and semaglutide in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing incidence of diabetes and obesity, expanding access to healthcare, and rising adoption of innovative treatments like liraglutide and semaglutide across the region. For instance, Merck reported in November 2022 that the FDA has approved once-weekly doses of dulaglutide (Trulicity) for the management of type 2 diabetes in pediatric patients ten years of age and older.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Healthcare professionals are increasingly adding liraglutide and semaglutide to complete treatment programs as a result of a growing understanding of the significance of lifestyle adjustment in the management of type 2 diabetes and obesity. These drugs are useful components of multimodal therapy approaches because they boost weight loss efforts in addition to helping manage blood sugar levels. For instance, in March 2023, Eli Lilly and Company reported favorable findings from a Phase 3 clinical trial assessing the safety and effectiveness of its once-weekly GLP-1 receptor agonist under consideration for weight management.
By type, the liquid segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the ease of administration and patient preference for injectable formulations, driving increased adoption and sales of liraglutide and semaglutide solutions. For instance, Novo Nordisk revealed encouraging findings from the SUSTAIN 11 trial in October 2022, proving the safety and effectiveness of once-weekly semaglutide in lowering significant adverse cardiovascular events in individuals with type 2 diabetes. Additionally, the pills segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience and patient preference for oral administration, as well as advancements in pill formulations improving efficacy and tolerability.
By route of administration, the parenteral segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the direct delivery of the medication into the bloodstream, ensuring rapid onset of action and precise dosing control, which are particularly beneficial for managing conditions like diabetes and obesity. For instance, in September 2023, Eli Lilly announced the start of the SURPASS-CVOT study, which aims to assess the cardiovascular efficacy and safety of tirzepatide with semaglutide in people with existing cardiovascular disease and type 2 diabetes. Additionally, the oral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for convenient and non-invasive treatment options, driving innovation in oral formulations, and expanding patient access to liraglutide and semaglutide therapies.
By application, the type 2 diabetes mellitus segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the growing prevalence of type 2 diabetes mellitus worldwide, driving the demand for effective glucose-lowering therapies such as liraglutide and semaglutide. For instance, AstraZeneca reported encouraging findings from the SURPASS-2 trial in December 2023, showing that once-weekly semaglutide significantly reduced HbA1c and body weight in persons with type 2 diabetes when compared to dulaglutide. Additionally, the obesity segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of obesity as a significant health concern and the efficacy of liraglutide and semaglutide in weight loss, driving greater adoption for obesity management.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global liraglutide and semaglutide market in 2023 owing to the preference for hospital-based administration of injectable medications like liraglutide and semaglutide, especially for acute management and closely monitored care of patients with diabetes and obesity-related complications. For instance, Sanofi announced in January 2024 the start of the AMPLITUDE-O study, which compares the safety and effectiveness of once-weekly semaglutide vs once-weekly efpeglenatide in individuals with type 2 diabetes. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of online platforms for medication purchases, the convenience of home delivery, and expanded access to liraglutide and semaglutide for patients in remote areas or with limited mobility.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of diabetes and obesity, robust healthcare infrastructure, and early adoption of advanced therapies like liraglutide and semaglutide in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly increasing incidence of diabetes and obesity, expanding access to healthcare, and rising adoption of innovative treatments like liraglutide and semaglutide across the region. For instance, Merck reported in November 2022 that the FDA has approved once-weekly doses of dulaglutide (Trulicity) for the management of type 2 diabetes in pediatric patients ten years of age and older.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Route of Administration, Application, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Liraglutide and Semaglutide Market Report 2023 - 2034
Liraglutide and Semaglutide Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Pills
- Liquid
Liraglutide and Semaglutide Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Parenteral
- Oral
Liraglutide and Semaglutide Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Type 2 Diabetes mellitus
- Obesity
- Others
Liraglutide and Semaglutide Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Liraglutide and Semaglutide Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Liraglutide and Semaglutide Market: Type Estimates & Trend Analysis
8. Liraglutide and Semaglutide Market: Route of Administration Estimates & Trend Analysis
9. Liraglutide and Semaglutide Market: Application Estimates & Trend Analysis
10. Liraglutide and Semaglutide Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Liraglutide and Semaglutide Market
13. Europe Global Liraglutide and Semaglutide Market
14. Asia Pacific Global Liraglutide and Semaglutide Market
15. Latin America Global Liraglutide and Semaglutide Market
16. MEA Global Liraglutide and Semaglutide Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Novo Nordisk
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Merck & Co. Inc.
- Boehringer Ingelheim
- GlaxoSmithKline plc (GSK)
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson
- Pfizer Inc.
- Novartis International AG
- Bristol Myers Squibb (BMS)
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Daiichi Sankyo Company
- Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 15.87 Billion |
| Forecasted Market Value ( USD | $ 51.83 Billion |
| Compound Annual Growth Rate | 11.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
